News stories about Zoetis (NYSE:ZTS) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zoetis earned a news impact score of 0.18 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.893881224019 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
Zoetis (NYSE ZTS) traded up $0.80 on Friday, hitting $75.39. The stock had a trading volume of 1,915,634 shares, compared to its average volume of 1,950,000. The company has a market cap of $36,740.00, a price-to-earnings ratio of 39.68, a price-to-earnings-growth ratio of 1.88 and a beta of 1.06. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. Zoetis has a 52-week low of $52.00 and a 52-week high of $75.69.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.02. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.52 EPS. research analysts forecast that Zoetis will post 2.37 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, January 19th will be given a $0.126 dividend. This represents a $0.50 annualized dividend and a dividend yield of 0.67%. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date of this dividend is Thursday, January 18th. Zoetis’s payout ratio is presently 22.11%.
ZTS has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated a “buy” rating and set a $75.00 price objective on shares of Zoetis in a report on Tuesday, September 26th. BidaskClub cut Zoetis from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 20th. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a report on Thursday, October 12th. Stifel Nicolaus restated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a report on Tuesday, October 24th. Finally, Jefferies Group reiterated a “buy” rating on shares of Zoetis in a report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $71.94.
COPYRIGHT VIOLATION WARNING: This story was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/01/13/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-zoetis-zts-share-price.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.